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SUMMARY 
rAAV vectors mediating long-term transgene expression are excellent gene therapy tools for 
chronic neurological diseases. While rAAV2 was the first serotype tested in the clinics, more 
efficient vectors deriving from the rh10 serotype are currently being evaluated and other serotypes 
are likely to be tested in the near future. In addition, aside from the currently used stereotaxy-guided 
intraparenchymal delivery, new techniques for global brain transduction (by intravenous or intra-
cerebrospinal injections) are very promising. 
Various strategies for therapeutic gene delivery to the CNS have been explored in human 
clinical trials in the past decade. Canavan disease, a genetic disease caused by an enzymatic 
deficiency, was the first to be approved. Three gene transfer paradigms for Parkinson’s disease have 
been explored : converting L-dopa into dopamine through AADC gene delivery in the putamen ; 
synthesizing GABA through GAD gene delivery in the overactive subthalamic nucleus; and 
providing neurotrophic support through Neurturin gene delivery in the nigro-striatal pathway. 
These pioneer clinical trials demonstrated the safety and tolerability of rAAV delivery in the 
human brain at moderate doses. Therapeutic effects however, were modest, emphasizing the need 
for higher doses of the therapeutic transgene product which could be achieved using more efficient 
vectors or expression cassettes. This will require re-addressing pharmacological aspects, with 
attention to which cases require either localized and cell-type specific expression or efficient brain-
wide transgene expression, and when it is necessary to modulate or terminate the administration of 
transgene product. The ongoing development of targeted and regulated rAAV vectors is described. 
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INTRODUCTION 
AAV vectors in the central nervous system 
The isolation of a molecular clone of adeno-associated virus (AAV) serotype 2  into the 
pBR322 plasmid by Samulski in 1982 opened the door for the genetic analysis of this virus [1] 
[2]. The origin of replication, consisting of the two 145-nucleotide non-coding extremities (the 
inverted terminal repeats, or ITRs) of the viral genome was shown to be the only cis-acting 
element needed for replication and encapsidation of the viral DNA and for rescue from plasmids. 
This discovery enabled the generation of recombinant AAV (rAAV) vectors through the cloning 
of heterologous genes instead of the AAV genes between the ITRs.  Recombinant viral particles 
are then produced by providing AAV genes and some helper adenoviral genes in trans [3] [4] [5] 
[6].
rAAV vectors are excellent tools in gene therapy for treatment of neurological diseases  as 
they transduce post-mitotic cells [7] [8] [9] that mediate the sustained, long-term gene expression 
[10] [11] that is required to treat chronic diseases. rAAV serotype 2 was the first discovered 
serotype and is still the best-understood but vectors deriving from several other human or simian 
serotypes have demonstrated both a higher efficiency and a wider distribution of transgene 
expression in the CNS [12] [13] [14]. 
rAAV vectors have an excellent safety profile [15].  First, they elicit only low titer and 
transient neutralizing antibodies and no inflammation when administered in the brain [10] [16]. 
Given the high seropositivity for AAV in the human population, this immune response against 
rAAV in the presence of circulating anti-AAV antibodies [17, 18], is a particularly important issue 
[19]. It has been demonstrated recently that after intraparenchymal injections into the CNS, 
transgene expression is unaffected in immune-primed mice harbouring physiologically-relevant 
anti-AAV2 antibodies levels [20]. Notably, there are significant differences in the immune 
responses toward the different AAV serotypes in the human population. In particular, healthy 
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donors present lower antibody titers against AAV5, AAV8 and AAV9 as compared to AAV2 and 
AAV1 [21]. In one study however, probably due to the infection of  antigen-presenting cells in the 
brain, high titer rAAV9 encoding non-self proteins elicited a strong cell-mediated and humoral 
immune response accompanied by a prominent inflammation [22]. Therefore, when using rAAV9 
encoding non-human proteins (such as engineered transasctivators; see below), the immune and 
inflammatory responses should be carefully evaluated. In addition, caution should be taken when 
interpreting data of rAAV9-mediated transfer of human cDNAs in animal models. 
Another risk, albeit a rare one, is vector DNA integration is a rare event resulting in a low 
risk of inadvertent oncogene activation [23]. Despite the increasing number of long-term studies in 
rodents and non human primates, none has reported deleterious DNA integration event in the brain 
[24]. In fact, increased tumor rates, clearly related to the vector  have only been evidenced in a 
particular tumor-prone model-in the liver- after a partial hepatectomy, both of which conditions 
artificially increase cell proliferation and DNA rearrangements [25]. 
After intraparenchymal delivery, rAAV vectors target mainly neurons in addition to a low 
percentage of glial cells depending on the transcriptional regulatory elements  [26] [27], the region 
[28] [29], the serotype [30] and the mode of delivery [31] [32] [33] [34] [35] [36] [37].  In a recent 
report, though, in striking contrast with previous studies [34] [35], rAAV9 intrastriatal delivery  has 
been shown to mediate transgene expression equally efficiently in astrocytes and neurons [22]. It 
should be noted, however, that the volume of virus injected by Ciesielska and coll. (i.e. 10 µl) was 
5-fold higher and the infusion speed 2.5-fold higher than in the other studies, conditions which 
might affect the transduction pattern [38]. 
The advent of new techniques for global brain transduction [39, 40] has opened new doors 
for the treatment of CNS diseases. These consists of injecting the virus intravenously exploiting the 
trans-blood-brain barrier delivery of rAAV9 [39] [32] [31] [41] or injecting it into the cerebrospinal 
fluid (CSF) via the cisterna magna [40]. With these new delivery modes, however, the immune and 
inflammatory responses to the vectors need to be revisited. In particular, it has been reported that 
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even a low neutralizing antibody titer in the blood of non-human primates abrogated transduction 
after intravenous delivery of rAAV9 [41]. Infusion of rAAV9 into the CSF via the cisterna magna 
led to dramatically stronger expression of the transgene and  a wider  distribution of gene transfer 
throughout the brain but, as with  intravenous injection, a significant preexisting anti-AAV antibody 
titer abrogated brain transduction [33]. 
Gene therapy clinical trials in the CNS with AAV 
Various strategies for therapeutic gene delivery to the CNS have been explored in pre-
clinical studies and in the past decade in human clinical trials. We will only illustrate the main 
strategies which have reached the clinics. More extensive reviews on rAAV-mediated gene transfer 
in the CNS have been published recently [9] [6] [42]. 
Canavan disease (CD), is a leukodystrophy caused by genetic mutations of the 
aspartoacylase (ASPA) gene, a metabolic enzyme restricted in the CNS to oligodendrocytes and it 
was the first disorder to be approved for AAV gene therapy in the CNS [43] [44]. ASPA deficiency 
results in accumulation of N-acetyl-aspartate in oligodendrocytes and subsequent 
hypomyelination/dysmyelination. Although the first clinical trial testing rAAV therapy on CD 
demonstrated no therapeutic effect, it did demonstrate the safety and tolerability of rAAV2 vectors 
delivery in the brain. In a subset (3/10) of CD subjects, low to moderate  levels of AAV neutralizing 
antibody with respect to baseline but, no increased inflammation or cellular immune response were 
reported [45]. These data suggest that, at the dose used (1 x 1012 vector genomes (vg) per patient)
and with intraparenchymal administration, the approach is relatively safe. Potential explanations for 
the lack of therapeutical effect are the low efficiency and restricted distribution of rAAV2-mediated 
transgene expression and the absence of transgene expression in oligodendrocytes . 
Correction of lysosomal enzyme deficiencies has also generated promising data. 
Late infantile neuronal ceroid lipofuscinoses (Batten Disease) is an autosomal recessive lysosomal 
storage disorder that results in progressive neurological degeneration. The disease is caused by 
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mutations in the CLN2 gene encoding a lysosomal tripeptidyl-peptidase whose deficiency causes 
accumulation of proteins in lysosomes of neurons leading to neuronal cell death.  A rAAV2 vector 
expressing the human CLN2 cDNA was administered to 12 locations in the CNS of 10 children, 
enrolled in a Phase I clinical trial for Batten disease. Although this trial was not double-blinded and 
randomized, the data suggested, on the basis of a neurologic rating scale, that the rate of decline was 
significantly reduced in treated patients [46]. On the basis of promising preclinical studies [47], 
another clinical trial using the more efficient AAVrh10 serotype has been launched 
(http://www.abedia.com/wiley/record_detail.php?ID=1717). 
Mucopolysaccharidosis type III (MPSIII), a disorder caused by the absence of one of the 
lysosomal enzymes required for the degradation of heparan sulfate (HS) which results in the 
accumulation of heparan sulfate oligosaccharides (HSOs) is also an interesting target for rAAV-
mediated  gene therapy. In MPSIIIB,  -N-acetylglucosaminidase (NaGlu) deficiency in particular 
is responsible for progressive mental neurodegeneration. Intracerebral stereotactic injections of 
AAV5 vectors coding for the missing enzyme reversed alterations of HS degradation, corrected 
pathology in neuronal cells and prevented neuroinflammation at the organ level in animal models 
[48]. Recently, a clinical trial using a rAAVrh10 vector has been launched for MPSIIIA, a 
deficiency in heparan-N-sulfamidase (http://www.abedia.com/wiley/record_detail.php?ID=318). 
Parkinson’s disease (PD) is also a good candidate for gene therapy since the main symptoms 
are caused by the progressive degeneration of a specific neuron population, the nigro-striatal 
dopaminergic (DA) neurons, located in a precise brain area, leading to the cardinal motor 
symptoms: bradykinesia, rigidity and tremor. Thanks to the discovery of the important role of 
dopamine depletion in PD, a breakthrough in the pharmacological treatment of PD was made in the 
1960s, in the form of the oral administration of L-dopa, the precursor to dopamine [49]. Exogenous 
L-dopa is taken up into the remaining functional DA neurons where it is converted into dopamine 
by aromatic acid decarboxylase (AADC). With the ongoing loss of DA neurons, though, the uptake 
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of extracellular L-dopa declines and increasing doses of L-dopa need to be administered leading to 
important fluctuations (e.g. peak-dose dyskinesias). Continuous delivery of L-dopa directly to the 
striatum via gene therapy could be a significant improvement because L-dopa would reach only the 
clinically relevant target area [50].  A rAAV2 vector expressing AADC has been injected in PD 
patients’ putamen in an attempt to reduce and stabilize the L-dopa dose necessary to alleviate the 
symptoms [51]. This combined treatment is predicted to provide more stable dopamine levels in the 
long-term than oral L-dopa treatment alone since AAV2-hAADC therapy results in expression of 
AADC in non-degenerating putaminal neurons [52], in contrast to nigral neurons that express 
endogenous AADC. Ten patients received bilateral intraputaminal infusions of 2 different doses of 
rAAV2-AADC (9 x 1010 and 3 x 1011 vg). Data based on PET imaging using a AADC-specific
tracer [51] fluoro-L-tyrosine) [53] demonstrated stable transgene expression over 4 years 
confirming the preclinical data on the longevity of rAAV-mediated transgene expression [11]. This 
clinical trial further confirmed the safety and tolerability of rAAV intracerebral administration [54] 
but emphasized the need for a higher vector dose.  The data showed dose-dependent improvements 
but even in the high-dose group in which the Unified Parkinson’s disease Rating Scale  (UPDRS) 
improved in all patients in the first 12 months, a slow deterioration was observed in subsequent 
years [53]. 
The motor abnormalities in PD are due to the overactivity of major output nuclei of the 
motor loop caused by the lack of dopamine in the striatum. Controlled inhibition of these 
excessively active nuclei can restore a normalized output to the cortex. Consistently, inhibiting the 
activity of the subthalamic nucleus (STN) by implanting adjustable electrodes provided impressive 
and immediate reversal of symptoms [55]. Using a similar paradigm, a rAAV2 vector expressing 
glutamic acid decarboxylase, the enzyme that synthesizes the inhibitory neurotransmitter GABA 
was injected in the STN. In preclinical studies, the vector transduced excitatory glutamatergic 
neurons which became inhibitory thereby reducing the STN activity [56]. A Phase I clinical trial 
demonstrated safety and tolerability of rAAV2 injections into the STN. Furthermore, 10 of 12 
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patients showed improvements in UPDRS at 12 months [57]. A subsequent double-blinded sham-
surgery controled trial involving 16 patients injected with AAV2-GAD and 21 receiving control 
sham-surgery, confirmed the UPDRS improvements [58]. In this study, in which 23 controls and 22 
treated patients were originally enrolled, in order to reinforce the statistical relevance of the data, 
the authors excluded from the analysis, the individuals for which identified technical failures 
occurred during the surgery. 
However effective, these therapeutic strategies might be, though, they are only 
compensatory and are not expected to interfere with DA neuron cell death. 
Providing neurotrophic support might constitute the first disease-interfering approach for 
PD. Glial cell line-derived neurotrophic factor (GDNF) and its analog Neurturin (NTN) were shown 
to protect and even in some instances restore DA neurons in most animal models (with the 
exception of alpha-synuclein overexpression [59]. Viral vectors expressing GDNF or NTN have 
been delivered in the striatum (Str) and the substantia nigra (SN) individually, and in both 
concurently. SN injections were efficiently protecting DA cell bodies but did not reverse motor 
symptoms due to the absence of enhanced striatal DA reinnervation [60] [61] [62]. In contrast, 
striatal injections protected both terminals and cell bodies and improve symptoms [61] [63] [64]. 
The fact that GDNF can be retrogradely transported from the striatum to the substantia nigra pars 
compacta [65] provides an interpretation for this observation. 
A rAAV2 vector expressing NTN is currently being evaluated in Phase II clinical trials [66]. 
In a first trial, the virus was injected in the putamen (5.4 x1011 vg per patient). At 12 months post-
surgery, no statistical improvement in the UPDRS parameters could be established but in a subset 
of patients reaching 18 months post-surgery, several parameters were significantly improved [67, 
68]. For 2 patients, post-mortem analysis revealed that NTN covered approximately 15% of the 
putamen.  Contrary to data obtained with similar amounts of virus in monkey, though, very few 
NTN-positive cells were detected in the SN of the treated patients, suggesting a poor retrograde 
transport of NTN [69]. It should be noted that the enrolled patients were at a late PD stage and that 
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virus quantities were very limited for safety reasons. A second clinical trial has been launched using 
both putamen and SN as delivery area (as in Kordower’s pioneer study, [63]) as well as a higher 
virus dose (2.4 x1012 vg per patient). Several preclinical [70] [71] [72] studies have described
adverse effects related to uncontrolled dosage and off-target delivery of GDNF. In addition, a 
clinical trial using minipumps to deliver recombinant GDNF protein in patients’ brain was 
interrupted due to the appearance of antibodies directed against GDNF [73]. Although none of these 
adverse effects have beed described so far in the AAV2-NTN gene therapy clinical trials, these 
observations raised the issue of the pharmacological aspects of rAAV-mediated gene delivery. 
A variety of vectors are being designed and continuously improved to adapt to the needs of 
these very diverse  situations. In some cases, localized (e.g GDNF)  and cell-type specific (e.g. 
GAD) expression is required whereas in cases like MPSIII, brain-wide and efficient transgene 
expression is a prerequisite to success. In some cases, such with as the correction of enzymatic 
deficiencies, maximizing transgene expression is the ultimate goal whereas in other cases, such with 
many neuroprotective strategies, it will be necessary to regulate transgene expression in order to 
adapt the dose of the transgene product to the patient’s needs and eventually terminate the 
treatment. The on-going development of better targeted and better regulated rAAV vectors is 
described in the following sections. 
REGULATION OF TRANSGENE EXPRESSION 
Several authors have reviewed the characteristics of an adequate system to regulate gene 
expression by exogenous drugs [74] [42] [75] [76]. An ideal regulatory system should harbour (a) a 
low basal activity in the uninduced state, (b) a high and inducer dose-dependent level of transgene 
expression in the induced state, (c) a rapid response to the administration or removal of the inducer, 
(d) a negligible toxicity, inflammatory response or immunogenicity associated with the regulatory 
elements, (e) absence of toxicity and good bioavailability of the inducing drug.  The latter depends 
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on the target organ and mode of administration of the drug. In this section, we will only review 
regulatable systems used to control gene expression into the brain using rAAV vectors. 
The constrained rAAV cloning capacity (~ 4.5 kb) limits the choice of regulatable systems. 
Drug-regulatable genetic systems usually comprise 2 elements : i) an inducible/repressible 
transcriptional promoter driving the expression of the transgene and ii) a genetically-engineered 
transactivator composed of a DNA-binding domain recognizing this promoter and interacting with 
the inducer, and an activator domain interacting with the cellular transcriptional machinery. Using 
two rAAV vectors to incorporate these 2 components separately requires that each cell is infected 
by both vectors at an optimal stoechiometry which is difficult to achieve in vivo [77] [78]. This has 
implications on the efficiency of transgene expression as the number of vector genomes rapidly 
decreases with distance from the injection site [26] [79]. Consistently the area covered by GDNF 
was considerably smaller despite a high vector dose (4.12x1010 vg) when using a dual-component
regulated rAAV [78] compared to single regulatable vector  [72] [26] [80]. 
The Tet-system (Fig.1) is the most widely used technology for drug-dependent regulation of 
gene expression in eukaryotes. Since its conception by Gossen and Bujard in 1992, [81] various 
improvements have been made to the different components of the Tet-system. The Tet-Off system 
(Fig.1A), the first developed Tet-regulatable version, utilizes the Escherichia coli Tetracycline-
repressor (TetR) protein fused to the activation domain of the herpes simplex virus type 1 (HSV1) 
VP16 transcription factor [81]. Being derived from a non-modified form of the TetR natural 
repressor, the Tet-Off system allows inhibition of transgene expression at a low inducer dose and 
has a low level of transgene expression in the non-induced state [82] [72]. However, the induction 
of expression in vivo is often slow and asynchronous because it requires complete removal of the 
inducer which depends on its half-life in the target organ [83, 84] [85] [82]. The half-life of 
elimination of doxycycline (Dox), a  tetracycline analog widely used to control the Tet-system, is 
about 3 days [86]. Improvements made to the Tet-Off transactivator were focused on the VP16 
activation domain to reduce its toxicity due to sequestering of transcriptional cellular factors [87]. 
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A reverse transactivator (rtTA) which, unlike the Tet-Off system, responds to the presence 
of Dox by activating transgene expression [88] has been obtained by modification of 4 amino acids 
of the TetR domain by random mutagenesis, resulting in a “Tet-On” version of the Tet-system 
(Fig.1B). Modifications focused on the rtTA to increase its performance involve introduction of a 
nuclear localization signal [89] [90], codon usage optimization [91] [92] [93], removal of potential 
splice sites  [91] and mutated activation domains [87] [91]. The most significant advances, 
however, came from the use of molecular evolution to identify improved rtTA mutants [94] [95]. 
Optimization of the cis-acting Tet-responsive promoter could also improve the Tet-system. 
Several modifications successfully reduced the basal activity of the Tet promoter [96] [97] [98] 
[99].  Usually, though, the decrease of the basal activity similarly affected the induced level of 
transgene expression. Interestingly, the latest developed Tet-promoter resulted in a low basal 
activity level while retaining a high activation potential [99]. 
Tet-regulatable rAAV vectors with different designs have been proposed, in order to avoid 
interferences with the transcriptional activity of the AAV ITR [100] and/or with the promoter used 
to express the Tet-transactivator [101] [102] [103] [104] [105] [72]. The size of the tetracycline-
responsive cis elements and transactivator (2.1kb) allows the inclusion of many therapeutic and 
reporter genes with a size up to 2.4kb.  Single vectors carrying the entire Tet-Off cassette have been 
used to regulate GFP [103] [104] [105] and GDNF [72] in healthy rat brain. In the latter case, an 
adverse effect of GDNF, weight loss, was shown to be tightly regulated by Dox [72]. Manfredsson 
and collaborators reported that the minimal Dox doses required to abrogate GDNF expression is 40 
mg Dox/kg diet (corresponding to 2.4 mg/ kg) in SN and 100 mg Dox/kg diet (corresponding to 6 
mg/ kg) in the striatum. The corresponding Dox serum levels were at least 8-fold lower than levels 
required for antimicrobial activity [106] and similar to those currently used as anti-inflammatory 
drug to treat rosacea [107], suggesting that clinically-acceptable Dox doses could be useful to 
regulate GDNF transgene expression in clinical trials. 
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Single rAAV using the Tet-On system were also described [101] [108] [80].  Using the 
rtTA2(S)M2 mutant developed by Urlinger, the quantity of Dox given to rats to achieve a biological 
effect was 600µg/ml in drinking water, equivalent to 70mg/kg for the GDNF transgene [108] [80] 
(Fig.2) and 3mg/kg for miRNA expression [101]. 
The constant antibiotics administration could lead to complications such as increased 
tolerance to tetracyclines or toxicity. Therefore, in order to minimize the period of treatment, the 
choice of an adequate version of the Tet-based system, will rely on the disease to be treated and the 
therapeutic strategy. 
Due to the blood-brain barrier (BBB), the effective inducer dose required for the biological 
effect of a transgene delivered into the brain is less feasible than for one delivered to the peripheral 
organs. To overcome this difficulty, attempts have been made to optimize the genetic components 
of the Tet system or to modify the transactivator to interact with inducers having better 
pharmacokinetics properties (in particular, crossing the BBB more efficiently). The identification of 
alternative Tet system inducers could i) provide a better control of gene expression, ii) avoid the 
effect of long-term exposure to tetracyclines, i.e. selection of resistant bacteria and destabilization 
of bowel flora [109] toxicity including phototoxicity and accumulation in bones [110] [111] and iii) 
improve bioavailability in the brain thanks to more efficient passage through the BBB. Besides 
Dox, other tetracyclines are able to induce the tTA and rtTA. Methacycline [112], has an induction 
potency similar to Dox with a shorter half-life [113] which is an advantage for faster clearance. 
Minocycline is also a good inducer for the tTA and some versions of the rtTA [112] [114] and 
furthermore has the advantage to be anti-inflammatory in the brain [115] [116].  4-epidoxycycline, a 
Dox metabolite without antibiotic activity which can induce the Tet-system [117] could also be an 
alternative. Chemically-modified tetracyclines (CMT) devoid of antibiotic activity [101] are also 
interesting but are not Tet-system inducers. Other inducers showing a higher affinity for 
rtTA2(S)M2 [91] than Dox on the basis of structural analysis while keeping the ability of Dox to 
cross the BBB have been discovered [118].  Finally, an alternative strategy to rapidly stop transgene 
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expression mediated by Tet-inducible vectors when the inducer’s half-life is a limiting factor, is GR 
33076X [119] a tetracycline antagonist able to competitively bind to the Tet transactivator. Notably, 
GR 33076X is not antibiotic and less toxic than other tetracyclines [119] [120]. 
The main disadvantage of the Tet system currently limiting its clinical use is the immune 
response elicited by the Tet transactivator. Indeed,  after intramuscular delivery by plasmid-, 
adenovirus- [121] or AAV-mediated expression [122] [123] into non-human primates, a rapid loss 
of transgene expression correlating with a cellular immune response has been described. However, 
the immune reactions in the brain, an immune-privileged site, could be substantially less efficient 
from those in other organs, [124] [125] [126]. Indeed, tTA [127] and rtTA2(S)M2 do not elicit 
striatal immune response even when rats are pre-immunized [124].  However, the rodent immune 
system does not correlate directly with that of humans and the vast majority of the human 
population (60%) has been exposed to herpes simplex virus [128].  They may thus have circulating 
antibodies against the VP16 portion of the tTA/rtTA, which could block transgene expression. The 
use of immunologically-humanized mice could help predict the immune response to the Tet 
transactivator in patients [129]. Attemps to replace the viral VP16-derived activator domain by the 
human p65 activation domain of the NFκB complex, could help reducing the immunogenicity of the 
Tet transactivator [130]. In this respect, the use of autoregulatory vectors avoiding permanent 
expression of Tet-transactivators constitutes an improvement [102] [103] [131]. Epitope analysis 
and subsequent predictive design of new less immunogenic transactivators could help minimizing 
the deleterious effect of pre-existing HSV-1 seropositivity. 
Another drug-inducible framework proposed for regulation AAV-mediated transgene 
expression in the brain is the rapamycin-inducible system [132]. However, until now this dual-
vector system provides transgene expression levels that are much lower than constitutive promoters 
[78]. 
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Methods to regulate transgene products posttranscriptionally have also been proposed. 
Although still in their infancy, it is worth citing: the regulation of protein stability through the 
binding of a small ligand, trimethoprim, to a destabilizing domain [133]. 
CELL TYPE-SPECIFICITY 
Numerous AAV capsid variants, either naturally occuring (serotypes) or laboratory-
engineered (by random mutagenesis or rationally-designed modifications), have been described [79] 
[134] [135] [136] [137] [138] [139] [140-143] [144] [145]. Capsid motifs are the key players in the 
interaction between viral particles and host cells mediating primary receptor attachment, secondary 
receptor-mediated cell entry and genome delivery to the nucleus, and as such, rAAV capsid variants 
are expected to differ in their cellular tropism. Interestingly, the variability between different 
serotypes is not evenly distributed along the capsid protein sequence but is higher in the domains 
that are displayed at the surface [146]. Thanks to the  technology for trans-encapsidation of rAAV2 
genomes into other serotype capsids [147], comparison between capsids without interferences due 
to the viral genome is possible. 
Numerous comparisons between serotypes were performed in the CNS of mice [13] [148] 
[14], rats [34] [12] [149], cats  [150] and non human primates [151] [152]. The majority of the 
tested serotypes or variants tested in rodents, mediate transgene expression mainly in neurons with 
the exception of AAVrh43 and rAAV4 which transduce  glial cells [153] and  ependymal cells 
[148]  respectively, when injected in the striatum. In contrast, in monkeys a high proportion of 
reporter gene positive glial cells were observed with rAAV5 [151] and rAAV1 [154] . 
In addition, different AAV serotypes transduce different neuronal subtypes. For example, in 
the rat hippocampus, rAAV2 targets dendate gyrus neurons whereas rAAV1 and 5 are more 
efficient in pyramidal neurons [12]. In the rat SN, rAAV2 mediates transgene expression 
exclusively in SN pars compacta [155] while rAAV1 and rAAV5 transduce pars compacta and 
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pars reticulata with similar efficiency[12]. Interestingly, the bb2 serotype transduces only medium 
spiny neurons in the rat striatum [153]. 
Other factors affecting  rAAV cellular specificity include : the promoter, the age of the 
animals and the purity of the viral preparation. For example, rAAV8 using constitutive promoters 
almost exclusively mediate neuronal expression in adult brain. However, contaminants present in 
the stocks affected the virus’ tropism resulting in a low propostion of astrocytes  [34]. The mode of 
delivery can also determine the cell-type specificity of rAAV-mediated transgene expression. When 
injected in the brain parenchyma, rAAV9 directs transgene expression mainly in neurons [34] [35]. 
In contrast, intravascular rAAV9 delivery results in a variable percentage of astrocytes expressing 
the transgene depending on the age of the animal, the species and the structure of the rAAV 
genome. Indeed, when injected in the facial vein of new born and adult C57Bl/6 mice, respectively, 
mainly neurons or astrocytes expressed the transgene [31]. In addition, Gray et al. [41] reported that 
self-complementary AAV9 (a double-stranded form of AAV genome generated using a mutant ITR; 
see below)  injected in the tail vein of adult BALB/c mice transduced twice as many neurons as 
astrocytes. This discrepancy might be explained by the injection site, the mice species or the 
genomic structure. Gray et al. further demonstrated that traditional single-stranded rAAV were far 
less efficient than self-complementary vectors. Finally, when the same vector was injected in the 
saphenous vein of non-human primate they observed a mainly astrocytic transduction [41]. 
Neuronal transduction was also reported by Duque and coll. in the spinal cord of adult mice after 
intravenous injection of self-complementary AAV9 in the temporal vein [32]. 
Differential rAAV cell-type specificity between fetal and adult brain was also reported.  In 
rat fetal midbrain striatal grafts, rAAV1 allowed massive transduction of DA neurons whereas 
rAAV2 exclusively transduced non-DA neurons (Fig. 2) contrasting with rAAV2 tropism for adult 
midbrain DA neurons [155]. Similarly, rAAV1 but not rAAV5 encapsidating the same viral 
genome transduced fetal striatal neurons, whereas both very efficiently transduced adult striatum 
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[156]. Interestingly, enhanced glial gene delivery in the brain has been obtained by selecting AAV 
capsid variants through molecular evolution [5]. 
In order to restrict transgene expression in target cell populations, different cell type-specific 
promoters were tested. For example, using rAAV2, the neuron-specific enolase promoter mediated 
restricted expression into neurons [10] whereas with the cytomegalovirus (pCMV) promoter, a 
small proportion of astrocytes also expressed the reporter gene. Similar results were obtained with 
the human synapsin I promoter (phSYN) [157]. As expected,  the tyrosine hydroxylase promoter 
allowed transgene expression restricted to DA neurons [158]. An elegant study using rAAV5-
encapsidated bicistronic vectors comprising one expression cassette using a promoter sequence 
derived from the murine CMV (pmCMV) and another under the control of phSYN showed that 
pmCMV drives expression in cells located in the striosomes (possibly oligodendrocytes) whereas 
phSYN-driven expression was strictly neuronal [159]. In an experiment using rAAV8 and 
rAAVrh43 in combination with the GFAP astrocytic promoter, or the myelin basic protein (MBP) 
promoter active in oligodendrocytes Lawlor observed an expression restricted to astrocytes with 
GFAP promoter with both serotypes. With MBP promoter, in contrast, they observed reporter gene 
expression mostly in oligodendrocytes with rAAV8 and in both astrocytes and oligodendrocytes 
with rAAVrh43. Surprisingly, when rAAVrh43 pMBP was injected into the hippocampus, a weak 
expression of the reporter gene was only observed in a subpopulation of dentate gyrus neurons 
[153] indicating the necessity to take into account cell-specific promoters and capsid variants  for 
targeting. 
Viral or composite promoters thought to be ubiquituous can also affect the cell-type 
specificity of rAAV-mediated transgene expression. We showed that rAAV1 mediate differential 
specificities of transgene expression depending on whether the expression is driven by a pCMV 
promoter or a by Tet-ON cassette [26]. For example, in the midbrain, transgene expression was 
restricted to the DA regions (SNpc and VTA) with the TetON system but was widespread in the 
midbrain with  pCMV. Promoter-related differential transduction has also been demonstrated in a 
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functional assay. In an epilepsy model, rAAV2 vectors expressing a NMDA receptor-1 (NR1) 
antisense under the control of pCMV and Tet-Off promoters caused an increase in seizures while 
pCMV-driven NR1 antisense expression lead to a significant reduction in seizures. Co-infusing 
these two vectors, each expressing a different reporter gene, demonstrated that they specify gene 
expression into different neuronal populations [131]. 
Intravascularly-administered rAAV6, rAAV8 and rAAV9 [58] are able to deliver genes to 
the brain. However, using this delivery mode, transgene expression is dramatically more efficient in 
the liver, spleen and heart than in the brain [41]. In order to restrict transgene expression to the 
CNS, Gao successfully repressed rAAV9 expression outside the CNS using a tissue-specific 
miRNA [160]. 
Another limiting step in rAAV-mediated gene delivery is the conversion of the single-
stranded viral DNA into a transcriptionally-active double-strand DNA. The synthesis of the second 
strand complementary to the viral DNA is mediated by cellular factors which are present in limiting 
concentrations depending on the cell type [79] ). Based on the discovery that (+) and (-) strand 
forms of AAV DNA are generated during the viral vector production [156], though, it has been 
proposed that when the genome copy number in a single cell is high enough, annealing of a sense 
sequence and an antisense sequence can occur. Based on the presence of dimeric  head-to- head 
replicative forms, McCarty [161] has introduced a mutation within one of the ITRs which forces the 
encapsidation of dimers rather than monomers The two head-to-head halves of vector genomes 
called "self-complementary" (scAAV) can anneal and form a double-strand mediating faster and 
more efficient transgene expression in the brain [162]. It should be noted that, due to limited 
packaging capacity, the maximal genome size of scAAV is reduced by half compared to 
conventional vectors. ScAAV2 and scAAV1injected in the brain parenchyma mediate a faster onset 
of- and a stronger transgene expression than AAV2 but do not seem to alter the cellular tropism 
[163] [164]. Similarly, scAAV9 injected i.v. in the mice shows an efficacy similar to a 20-fold 
higher dose of AAV9 [41]. 
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CONCLUSIONS 
Various strategies for therapeutic gene delivery to the CNS have been explored. Aside from 
correction of recessive genetic defects [53] [165] [29] or gene silencing through RNA interference 
in autosomal dominant diseases [77] [6], gene transfer paradigms for diseases not having a clearly 
identified genetic origin have been explored. Interestingly, three different gene therapy approaches 
for sporadic PD have entered the clinics: converting L-dopa into dopamine through AADC gene 
delivery in the putamen [53]; synthesizing GABA through GAD gene delivery in the subthalamic 
nucleus [57] and providing neurotrophic support through Neurturin gene delivery in the nigro-
striatal pathway [67]. It is worth citing another clinical trial for Parkinson’s disease using a 
lentiviral vector which, like the AAV2-AADC gene therapy, encodes enzymes of the dopamine 
biosynthetic pathway. However, taking advantage of the larger cloning capacity of lentiviral vectors 
as compared to rAAV vectors,  the 3 main enzymes required to achieve dopamine biosynthesis from 
tyrosine, i.e tyrosine hydroxylase, aromatic-L-acid decarboxylase (AADC) and GTP-
cyclohydrolase I could be encoded in a single vector [166]. A clinical trial in which this vector is 
injected in the patients’ putamen is ongoing 
(http://www.abedia.com/wiley/record_detail.php?ID=310). 
In some cases, localized and cell-type specific expression is required. For example, the 
success of the rAAV2-GAD paradigm relies on the targeting of STN excitatory neurons to turn 
them into inhibitory neurons. In addition, off-target delivery  might result in side effects. A clear 
demonstration was provided by Haberman and McCown showing that transferring a NMDA 
receptor anti-sense in different types of neurons may result in opposite behavioral effects [131]. 
Rationally-based targeting can be achieved by capsid engineering [136] [5] [167] or miRNA 
restricted-transgene expression [168]. In the case of  motoneurons diseases, targeting can also be 
achieved through retrograde delivery [79] [129]. 
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In other cases, in particular for enzymatic deficiencies, global and efficient transgene 
expression is a prerequisite to success. However, though global brain transduction is searched, cell-
type specificity might still be a limitation.  In leukodystrophies, for example,  the missing enzyme 
must be supplied to oligodendrocytes [29]. Since the majority of gene therapy vectors, including 
rAAVs, transduce mostly neurons after intraparenchymal delivery in most brain regions  [169] [12] 
[34] [155] [13], the derivation of vectors efficiently targeting oligodendrocytes is still a challenging 
issue. Interestingly, in regions that do not harbor neurons, such as the internal capsule or corpus 
callosum, glial cells are readily transduced [28] [27] [29]. On the other hand ,intravenous or intra-
CSF delivery, results in astrocytic in addition to neuronal transduction [32] [31] [41]. A small 
degree of co-labeling between GFP and Olig1 (an marker for oligodendrocytes) is also mentioned in 
the last study [41].In contrast, in none of these reports were microglia transduced. 
Pioneer clinical trials have established the safety and tolerability of rAAV2 delivery in the 
human brain at moderate doses. Therapeutic effects however, were modest, emphasizing the need 
for more efficient vectors and/or higher doses. More recently, clinical trials using AAVrh10 vectors 
for Batten disease ( http://www.abedia.com/wiley/record_detail.php?ID=1717) and MPSIIIA 
(http://www.abedia.com/wiley/record_detail.php?ID=318) have been launched. Vectors deriving 
from other serotypes mediating efficient and widespread transgene expression are likely to be tested 
in patients in the near future. In addition, aside from the currently used stereotaxy-guided  
intraparenchymal delivery [170], new techniques for global brain transduction (by intravenous or 
intra-CSF injections) are very promising [171] [39]. These new vectors and delivery routes will 
require re-addressing the pharmacological aspects of rAAV-mediated gene transfer. 
Adverse effects of uncontrolled or off-target delivery of neurotrophic factors have been 
described [71] [73] [42, 172]. With the launching of clinical trials for neuroprotective gene therapy 
with increasing vector doses [66], regulation of transgene expression will likely be required to avoid 
adverse events and, if necessary, terminate the treatment. Among the regulatable systems, the Tet-
system is the most widely used and the best-developed [42]. However, important issues remain to 
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be solved. First, immune reactions to the VP16 portion of the Tet transactivator deriving from HSV 
are likely to arise in HSV-seropositive patients. Second, the inducer should be a clinically-approved 
molecule effective at a clinically-acceptable dose. The last developments of rAAV-based Tet-Off 
vectors, have shown regulation of an adverse effect of GDNF (weight loss) using a Dox dose which 
is below the approved anti-microbial dose [72]. However, therapeutical effects have not been 
addressed in this study. On the other hand, using a rAAV-tetON vector, Dox-dependent behavioral 
improvements have been demonstrated in a well-established rodent model of PD [80]. In this study, 
though, the Dox dose, by body mass was more than one order of magnitude higher than the 
approved dose for patients. The remaining challenges will be to characterize and eventually 
circumvent the immune reaction to the Tet transactivator as well as to obtain inducer-transactivator 
interactors fulfilling clinical requirements. 
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LEGENDS TO FIGURES 
 
Figure 1. 
A, Tet-Off system: in the absence of doxycycline the tTA transactivator binds to the tetO (tet 
operator) repeated sequence and activates transcription from the minimal promoter (PhCMVmini) of 
human cytomegalovirus (hCMV). B, Tet-On system: in the presence of doxycycline the rtTA 
transactivator binds to the tetO repeated sequence and activates transcription from the minimal 
PhCMVmini promoter. Ptet is a fusion of seven repeated tetO sequence (7x42pbs) and the PhCMVmini.  
The PhCMVmini. corresponds to the hCMV promoter without its enhancers sites. The (reverse) 
transactivator (r) tTA is composed of the (reverse) Tetracycline Repressor ((r)TetR) of the Tn10 
tetracycline resistance operon of Escherichia coli and a portion of herpes simplex virus (HSV) 
protein 16 that functions as a potent activator of transcription. 
 
Figure 2. 
Regulation of GDNF transgene expression mediated by a single AAV-tetON tetracycline-inducible 
vector in the striatum in a partial rat model of PD. 
A single injection of rAAV2/1-tetON-GDNF (3.5 x 108 vg/rat) was performed in the rat striatum. 
One month later, a 4-injection sites 6-hydroxydopamine lesion [61] was performed. Animals were 
continuously treated with doxycycline (A) (600 µg/l in drinking water)or remained untreated (B) 
and were sacrified one month post-lesioning.     




Differential cellular tropism of rAAV2/1 and rAAV2/2-mediated gene transfer into fetal ventral 
mesencephalon grafted in adult rat striatum. 
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The ventral mesencephali (VM) from 14-days embryos were dissected out and infected with rAAV 
vectors expressing eGFP reporter gene under the control of CMV promoter, trans-encapsidated into 
AAV1 ( rAAV1-pCMV-eGFP) or AAV2 ( rAAV2/2-pCMV-eGFP) capsids. Immediately after 
infection, VMs were dissociated into individual cells and animals were stereotactically infused into 
the right striatum with a cell suspension corresponding from the half of a VM per rat, as previously 
described [173] .  
Four weeks posttransplantation, animals were sacrificed and 40-µm coronal brain sections were 
labeled using polyclonal rabbit anti-GFP antibodies (green fluorescence) and monoclonal anti-
tyrosine hydroxylase antibodies (red fluorescence). Double-labeled cells appear yellow. 
Scale bar : 100µm (10X pictures) and 50 µm (40X pictures).  
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